HALO:NGS-Halozyme Therapeutics Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 52.36

Change

+0.73 (+1.41)%

Market Cap

USD 1.64B

Volume

2.33M

Analyst Target

USD 33.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Halozyme Therapeutics Inc is a biopharmaceutical company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.29B
ARGX argenx NV ADR

N/A

USD 32.06B
MRNA Moderna Inc

N/A

USD 25.25B
BGNE BeiGene Ltd

N/A

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

N/A

USD 15.95B
SMMT Summit Therapeutics PLC

N/A

USD 15.35B
PCVX Vaxcyte Inc

N/A

USD 14.00B

ETFs Containing HALO

ROYL:AU BetaShares Global Royalti.. 4.63 % 0.00 %

N/A

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 3.35 % 0.00 %

N/A

USD 0.02B
BIOT:SW L&G Pharma Breakthrough U.. 3.12 % 0.00 %

N/A

N/A
HLTH:AU VanEck Global Healthcare .. 2.95 % 0.00 %

N/A

USD 0.06B
FSCC Federated Hermes ETF Trus.. 1.84 % 0.00 %

N/A

N/A
SCDS JPMorgan Fundamental Data.. 1.49 % 0.00 %

N/A

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.59 % 0.00 %

N/A

USD 1.19B
VTWG Vanguard Russell 2000 Gro.. 0.59 % 0.20 %

N/A

USD 1.02B
AGED:SW iShares Ageing Population.. 0.57 % 0.00 %

N/A

N/A
RTWO:LSE L&G Russell 2000 US Small.. 0.47 % 0.00 %

N/A

USD 0.15B
RTWP:LSE Legal & General UCITS ETF.. 0.47 % 0.00 %

N/A

USD 0.15B
ETLZ:XETRA L&G Russell 2000 US Small.. 0.47 % 0.00 %

N/A

USD 0.09B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.30 % 0.00 %

N/A

USD 3.31B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.30 % 0.00 %

N/A

USD 3.31B
R2US:PA SSgA SPDR ETFs Europe II .. 0.30 % 0.00 %

N/A

USD 3.34B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.30 % 0.00 %

N/A

USD 2.91B
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.30 % 0.00 %

N/A

USD 2.91B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.30 % 0.00 %

N/A

USD 1.38B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.30 % 0.00 %

N/A

USD 1.38B
XRS2:F Xtrackers (IE) Public Lim.. 0.30 % 0.00 %

N/A

USD 1.19B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.30 % 0.00 %

N/A

USD 1.19B
XRS2:SW Xtrackers Russell 2000 UC.. 0.30 % 0.00 %

N/A

USD 1.38B
RSSL Global X Funds 0.30 % 0.00 %

N/A

N/A
VRTIX Vanguard Russell 2000 Ind.. 0.29 % 0.00 %

N/A

USD 10.02B
VTWO Vanguard Russell 2000 Ind.. 0.29 % 0.15 %

N/A

USD 11.71B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

N/A
GSC Goldman Sachs ETF Trust 0.00 % 1.25 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

N/A
PSC Principal U.S. Small-Cap .. 0.00 % 0.38 %

N/A

USD 0.65B
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

N/A
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

N/A

USD 0.46B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

N/A
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 41.67% 85% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.67% 85% B 90% A-
Trailing 12 Months  
Capital Gain 45.16% 84% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.16% 84% B 89% A-
Trailing 5 Years  
Capital Gain 204.77% 91% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 204.77% 91% A- 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 30.35% 79% B- 85% B
Dividend Return 30.35% 79% B- 85% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.09% 54% F 32% F
Risk Adjusted Return 58.27% 96% N/A 84% B
Market Capitalization 1.64B 97% N/A 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 20.86 27% 44%
Price/Book Ratio 58.55 3% 2%
Price / Cash Flow Ratio 16.47 4% 16%
Price/Free Cash Flow Ratio 13.43 3% 19%
Management Effectiveness  
Return on Equity 261.68% 100% 100%
Return on Invested Capital 16.62% 89% 85%
Return on Assets 13.48% 100% 97%
Debt to Equity Ratio 1,788.91% 1% 0%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.